Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Valiltramiprosate (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Acronyms APOLLOE4
- Sponsors Alzheon
- 26 Mar 2024 According to an Alzheon media release,data from this trial published in the International Journal of Molecular Sciences,this trial expected to be completed in mid of 2024.
- 27 Feb 2024 According to an Alzheon media release, data from this trial will be presented at the upcoming International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in Lisbon, Portugal from March 5-9, 2024.
- 03 Jan 2024 According to an Alzheon media release, the Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program